News for FBIO Stock

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform Journey Medical Corporation to Participate in the 37th Annual ROTH Conference Sun Pharma to Acquire Checkpoint Therapeutics Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference Fortress Biotech to Participate in October 2024 Investor Conferences Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 Journey Medical Corporation to Participate in the 36th Annual ROTH Conference Fortress Biotech to Participate in 36th Annual ROTH Conference Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Fortress Biotech Announces Closing of $10.0 Million Public Offering Fortress Biotech Announces Pricing of $10.0 Million Public Offering Fortress Biotech Announces Launch of Proposed Public Offering Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) Fortress Biotech Announces Reverse Stock Split Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023 Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023 Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023 Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023 Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023 Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023 Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial Journey Medical Corporation to Participate in the 35th Annual ROTH Conference Fortress Biotech to Participate in Two March 2023 Investor Conferences Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29 Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022 Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022 Fortress Biotech Appoints David Jin as Chief Financial Officer Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022 Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022 Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea Fortress Biotech to Participate in Three March 2022 Investor Conferences Journey Medical Corporation to Present at the 34th Annual ROTH Conference Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation Fortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc. Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21 Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease Journey Medical Corporation Introduces Expanded Board of Directors Journey Medical Corporation Announces Closing of Initial Public Offering Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) Journey Medical Corporation Prices $35.2 Million Initial Public Offering Journey Medical Corporation Announces Launch of its Initial Public Offering Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference Fortress Biotech to Participate in Three September 2021 Investor Conferences Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences Fortress Biotech Announces Webinar Hosted by ROTH Capital Partners Featuring Partner Company Journey Medical Corporation REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West Bank Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA® Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease Fortress Biotech Announces Pricing of Series A Preferred Stock Offering Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020 Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease Fortress Biotech Added to Russell 3000® Index Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports Fortress Biotech to Present at the Raymond James Human Health Innovation Conference Fortress Biotech Announces Pricing of Series A Preferred Stock Offering